Bruton's Tyrosine Kinase | Protein Tyrosine Kinase/RTK| CSNpharm

BTK

BTK
第页，共 2 页

货号	产品名	CAS号	信息
CSN22147	Zanubrutinib	1691249-45-2	Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.
CSN22532	Vecabrutinib	1510829-06-7	Vecabrutinib is a potent BTK inhibitor, with IC50s of 4.6 nM and 1.1 nM for WT BTK and C481S BTK, respectively, and also inhibits ITK activity (IC50, 24 nM).
CSN28458	SJF620	2376187-16-3	SJF620 is a potent PROTAC BTK degrader with a DC50 of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.
CSN15892	RN486	1242156-23-5	RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
CSN32900	Rilzabrutinib	1575591-66-0	Rilzabrutinib is a BTK inhibitor.
CSN50327	Remibrutinib	1787294-07-8	Remibrutinib is an effective and highly selective inhibitor of Bruton tyrosine kinase (Btk).
CSN13816	QL47	1469988-75-7	QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.
CSN20296	Poseltinib	1353552-97-2	Poseltinib is a tyrosine kinase inhibitor of Bruton's tyrosine kinase (BTK).
CSN28522	BTK PROTAC 9	2250382-64-8	PON82648, also known as BTK PROTAC 9, is a PROTAC for BTK.
CSN20637	PLS-123	1431727-04-6	PLS-123 is a covalent irreversible Btk inhibitor with potential anti-proliferative activity.
CSN32454	Pirtobrutinib	2101700-15-4	Pirtobrutinib is a highly selective and non-covalent BTK inhibitor, which may be regarded as a third generation BTK inhibitor. It potently inhibited the cellular activity (measured by Y223 autophosphorylation) of BTK C481S, T and R mutations and displayed strong equilibrium binding to WT BTK and several BTK C481 substitution mutations. It may overcome acquired resistance to covalent BTK inhibitors in patients without significant off-target toxicity.
CSN24174	PF-06250112	1609465-89-5	PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5nM, 0.9nM and 1.2nM for BTK, BMX Kinase and TEC, respectively.
CSN18605	Ibrutinib Racemate	936563-87-0	PCI-32765 racemate is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
CSN18219	PCI 29732	330786-25-9	PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
CSN28511	P13I	2360561-66-4	P13I is a novel PROTAC BTK degrader, efficiently degrading ibrutinib-sensitive BTK-WT (wild type), significantly inducing the degradation of ibrutinib-resistant BTK-C481S.
CSN27283	Orelabrutinib	1655504-04-3	Orelabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
CSN17862	Tirabrutinib hydrochloride	1439901-97-9	ONO-4059 is a selective inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.
CSN17733	Tirabrutinib	1351636-18-4	ONO-4059 is a highly selective BTK inhibitor with IC50 of 2.2 nM.
CSN17732	ONO-4059 analog	1351635-67-0	ONO-4059 Analog is a highly selective BTK inhibitor with IC50 of 2.2 nM.
CSN22302	MT-802	2231744-29-7	MT-802 (MT802) is a potent BTK PROTAC that induces degradation of both wild-type and C481S mutant BTK (DC50=9.1 nM); MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome; MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK, elicits complete BTK knockdown at 250 nM; reduces the pool of active, phosphorylated BTK in cells isolated from CLL patients with the C481S mutation, whereas ibrutinib cannot.
CSN21709	LFM-A13 (mixture)	62004-35-7	LFM-A13 is specific inhibitor of bruton’s tyrosine kinase (BTK) with IC50 of 17.2 µM and 2.5 µM for recombinant BTK.
CSN19154	Ibrutinib-biotin	1599432-18-4	Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, with an IC50 of 0.755-1.02 nM for BTK.
CSN19159	Fenebrutinib	1434048-34-6	GDC-0853 is a potent and orally BTK inhibitor.
CSN13839	GDC-0834 S-enantiomer	1133432-50-4	GDC-0834 S-enantiomer is the S-enantiomer of GDC-0834.
CSN17489	GDC-0834 Racemate	1133432-46-8	GDC-0834 racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
CSN17490	GDC-0834	1133432-49-1	GDC-0834 is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
CSN17176	CNX-774	1202759-32-7	CNX-774 is a potent and selective of Btk with IC50 < 1 nM.
CSN18870	CHMFL-BTK-01	2095280-64-9	CHMFL-BTK-01 is an irreversible BTK inhibitor targeting Cys481 residue while completely abolishing BMX, JAK3 and EGFR's activity.
CSN13815	CGI-1746	910232-84-7	CGI-1746 is a Bruton's tyrosine kinase (Btk) inhibitor.
CSN22295	BTK PROTAC 9	N/A	BTK PROTAC 9 is a potent PROTAC for BTK with DC50 of 5.9 nM in cultured Ramos cells, requires simultaneous engagement of BTK and CRBN to effectively degrade BTK; TEC, a closely related protein to BTK that potently binds BTK PROTAC 9 is also degraded.
CSN22294	BTK PROTAC 10	N/A	BTK PROTAC 10 is a potent PROTAC for BTK with DC50 of 1.1 nM in cultured Ramos cells; can successfully delivered to tissues and can specifically degrade BTK in vivo, in a dose-dependent and tissue-biased manner by s.c. administration.
CSN25627	BTK inhibitor 4b	1646608-10-7	BTK inhibitor 4b is a highly selective BTK inhibitor with significant efficacy in models in vivo and good ADME and safety profiles.
CSN13705	IBT6A	1022150-12-4	Btk inhibitor 1 R-enantiomer is a Btk kinase inhibitor.
CSN17926	IBT6A hydrochloride	1553977-42-6	Btk inhibitor 1 R-enantiomer HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CSN17811	(Rac)-IBT6A	1412418-47-3	Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CSN19157	Btk inhibitor 1 HCl	1807619-60-8	Btk inhibitor 1 HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CSN24501	BTK IN-1	1270014-40-8	BTK IN-1 is a potent BTK inhibitor, with an IC50 of <100 nM.
CSN24257	Branebrutinib	1912445-55-6	BMS-986195 is a potent, covalent, irreversible BTK inhibitor with IC50 value of 0.1nM.
CSN20297	BMS-986142	1643368-58-4	BMS-986142 is a potent, selective, reversible BTK inhibitor. BMS-986142 shows BTK IC50 = 0.5nM and human WB IC50 = 90 nM.
CSN19767	BMS-935177	1231889-53-4	BMS-935177 is a potent BTK inhibitor with improved kinase selectivity and superior oral exposure in multiple species. should provide useful clinical efficacy in autoimmune diseases.
CSN20168	(±)-Zanubrutinib	1633350-06-7	BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.
CSN16215	Spebrutinib	1202757-89-8	AVL-292 is a covalent and highly selective inhibitor of Btk with IC50 of 0.5 nM, exhibiting > 1400-fold selectivity over the other kinases assayed.
CSN17749	Spebrutinib besylate	1360053-81-1	AVL-292 benzenesulfonate is a potent inhibitor of Btk kinase activity (IC50< 0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays.
CSN26602	XMU-MP-3	2031152-08-4	ATP, respectively. XMU-MP-3 also induces apoptosis[1].
CSN21093	ARQ 531	2095393-15-8	ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity.
CSN16252	Acalabrutinib	1420477-60-6	Acalabrutinib is a second-generation, selective and irreversible inhibitor of BTK (Bruton's tyrosine kinase) with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay. Acalabrutinib has improved pharmacologic features, including favorable plasma exposure, rapid oral absorption, a short half-life, and the absence of irreversible targeting to alternative kinases.
CSN22895	Terreic acid	121-40-4	(-)-Terreic Acid is a selective inhibitor of Bruton's tyrosine kinase (BTK).
CSN28534	DD 03-171	2366132-45-6	Potent and selective BTK Degrader (PROTAC®)
CSN51412	BCPyr	2669844-82-8

<< PREV 1 2 NEXT >>

BTK 第 1 2 页，共 2 页

BTK
第页，共 2 页